Subtopic Deep Dive

IgG4-Related Sclerosing Cholangitis
Research Guide

What is IgG4-Related Sclerosing Cholangitis?

IgG4-related sclerosing cholangitis is a biliary manifestation of IgG4-related disease characterized by bile duct strictures, elevated serum IgG4 levels, and dense IgG4-positive plasma cell infiltration, often steroid-responsive and distinguishable from primary sclerosing cholangitis.

This condition involves obliterative phlebitis and storiform fibrosis in biliary tracts (Zen et al., 2004). It frequently coexists with sclerosing pancreatitis and hepatic inflammatory pseudotumors (Hamano et al., 2001; 2688 citations). Over 500 papers explore its pathology and treatment since 2001.

15
Curated Papers
3
Key Challenges

Why It Matters

IgG4-related sclerosing cholangitis enables targeted steroid therapy, preventing unnecessary liver transplantation by distinguishing it from malignancies or primary sclerosing cholangitis (Zen et al., 2004; 538 citations). Rituximab provides rapid IgG4 decline and symptom relief in refractory cases (Khosroshahi et al., 2010; 518 citations). Accurate diagnosis via serum IgG4 and histology averts invasive procedures, improving outcomes in multi-organ IgG4-RD (Deshpande et al., 2012; 2497 citations).

Key Research Challenges

Distinguishing from PSC

IgG4-related sclerosing cholangitis mimics primary sclerosing cholangitis radiologically, requiring serum IgG4 and biopsy for differentiation. Multi-focal strictures and steroid response aid diagnosis (Zen et al., 2004). Imaging alone often fails to separate entities (Okazaki et al., 2006).

Heterogeneous organ involvement

Biliary disease associates variably with pancreatitis or pseudotumors, complicating staging. Hepatic pseudotumors mimic tumors (Zen et al., 2004; 538 citations). Long-term relapse post-steroids demands surveillance (Hart et al., 2012).

Pathology standardization

Consensus criteria define IgG4+ plasma cells >10/hpf and IgG4/IgG >40%, but interobserver variability persists (Deshpande et al., 2012; 2497 citations). Th2 immune patterns confirm diagnosis (Zen et al., 2007; 645 citations).

Essential Papers

1.

High Serum IgG4 Concentrations in Patients with Sclerosing Pancreatitis

Hideaki Hamano, Shigeyuki Kawa, Akira Horiuchi et al. · 2001 · New England Journal of Medicine · 2.7K citations

Patients with sclerosing pancreatitis have high serum IgG4 concentrations, providing a useful means of distinguishing this disorder from other diseases of the pancreas or biliary tract.

2.

Consensus statement on the pathology of IgG4-related disease

Vikram Deshpande, Yoh Zen, John K. C. Chan et al. · 2012 · Modern Pathology · 2.5K citations

3.

Inflammatory myofibroblastic tumours: where are we now?

Briana C. Gleason, Jason L. Hornick · 2007 · Journal of Clinical Pathology · 735 citations

Inflammatory pseudotumour is a generic term applied to a variety of neoplastic and non-neoplastic entities that share a common histological appearance, namely a cytologically bland spindle cell pro...

4.

A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details

Hisanori Umehara, Kazuichi Okazaki, Yasufumi Masaki et al. · 2011 · Modern Rheumatology · 718 citations

IgG4-related disease (IgG4RD) is a novel clinical disease entity characterized by elevated serum IgG4 concentration and tumefaction or tissue infiltration by IgG4-positive plasma cells. IgG4RD may ...

5.

Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis

Yoh Zen, Takahiko Fujii, Kenichi Harada et al. · 2007 · Hepatology · 645 citations

Immunoglobin G (IgG) 4-related sclerosing pancreatitis and cholangitis (autoimmune pancreato-cholangitis [AIPC]) are recently recognized disease entities characterized by high serum IgG4 concentrat...

6.

Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal

Kazuichi Okazaki, Shigeyuki Kawa, Terumi Kamisawa et al. · 2006 · Journal of Gastroenterology · 585 citations

atic duct and diffuse enlargement of the entire pancreas due to lymphocyte infiltration.In 1995, Japanese investigators 3 firstly proposed a concept of "autoimmune pancreatitis (AIP)", in which the...

7.

Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis

Phil A. Hart, Terumi Kamisawa, William R. Brugge et al. · 2012 · Gut · 561 citations

Objective Autoimmune pancreatitis (AIP) is a treatable form of chronic pancreatitis that has been increasingly recognised over the last decade. We set out to better understand the current burden of...

Reading Guide

Foundational Papers

Start with Hamano et al. (2001; 2688 citations) for IgG4 discovery in sclerosing diseases, then Deshpande et al. (2012; 2497 citations) for pathology standards, followed by Zen et al. (2004; 538 citations) for cholangitis specifics.

Recent Advances

Study Zen et al. (2007; 645 citations) on Th2 immunity, Khosroshahi et al. (2010; 518 citations) on rituximab, and Hart et al. (2012; 561 citations) on outcomes.

Core Methods

Serum IgG4 ELISA, ERCP/MRCP imaging, immunohistochemistry for IgG4+ cells, steroid responsiveness testing (Okazaki et al., 2006; Umehara et al., 2011).

How PapersFlow Helps You Research IgG4-Related Sclerosing Cholangitis

Discover & Search

Research Agent uses searchPapers and exaSearch to find 500+ papers on IgG4 cholangitis, then citationGraph on Hamano et al. (2001; 2688 citations) reveals Zen et al. (2004) connections for biliary-specific literature. findSimilarPapers expands to pseudotumor overlaps.

Analyze & Verify

Analysis Agent applies readPaperContent to extract IgG4 thresholds from Deshpande et al. (2012), verifies claims with CoVe against 10 similar papers, and uses runPythonAnalysis for meta-analysis of serum levels via pandas on extracted data. GRADE grading scores evidence strength for steroid response claims.

Synthesize & Write

Synthesis Agent detects gaps in rituximab long-term data post-Khosroshahi et al. (2010), flags contradictions in relapse rates. Writing Agent employs latexEditText for case reports, latexSyncCitations for 20-paper reviews, and latexCompile for publication-ready manuscripts with exportMermaid for pathology flowcharts.

Use Cases

"Extract serum IgG4 levels from IgG4 cholangitis cohorts and compute diagnostic thresholds"

Research Agent → searchPapers('IgG4 sclerosing cholangitis serum levels') → Analysis Agent → readPaperContent(Zen 2004, Hamano 2001) → runPythonAnalysis(pandas meta-analysis, matplotlib ROC curve) → statistical thresholds and sensitivity plot.

"Write LaTeX review comparing IgG4 cholangitis vs primary sclerosing cholangitis"

Synthesis Agent → gap detection → Writing Agent → latexEditText(structured sections) → latexSyncCitations(Deshpande 2012, Zen 2007) → latexCompile → PDF with bile duct diagrams via latexGenerateFigure.

"Find code for analyzing IgG4 pathology slide images in cholangitis papers"

Research Agent → paperExtractUrls(Zen 2004) → paperFindGithubRepo → Code Discovery → githubRepoInspect → validated image segmentation code for IgG4+ cell counting.

Automated Workflows

Deep Research workflow scans 50+ papers via searchPapers on 'IgG4 cholangitis steroid response', structures report with GRADE scores and citationGraph. DeepScan applies 7-step CoVe to verify pathology criteria from Deshpande et al. (2012). Theorizer generates hypotheses on Th2 mechanisms from Zen et al. (2007).

Frequently Asked Questions

What defines IgG4-related sclerosing cholangitis?

It features biliary strictures, serum IgG4 >135 mg/dL, and histopathology with >10 IgG4+ cells/hpf (Deshpande et al., 2012). Storiform fibrosis and obliterative phlebitis confirm diagnosis (Zen et al., 2004).

What are key diagnostic methods?

Combine elevated serum IgG4, imaging strictures, and biopsy showing IgG4+ infiltrates (Hamano et al., 2001). Steroid trial assesses response (Okazaki et al., 2006).

What are landmark papers?

Hamano et al. (2001; 2688 citations) linked IgG4 to sclerosing pancreatitis/cholangitis. Deshpande et al. (2012; 2497 citations) set pathology consensus. Zen et al. (2004; 538 citations) detailed biliary histology.

What open problems remain?

Optimal rituximab dosing for relapse and biomarkers beyond IgG4 need validation (Khosroshahi et al., 2010). Long-term outcomes post-remission unclear (Hart et al., 2012).

Research IgG4-Related and Inflammatory Diseases with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching IgG4-Related Sclerosing Cholangitis with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers